Subscribe

Advertisement

Cervical Cancer

Relevant Articles About Cervical Cancer Research and Clinical Trials

RELATED :Ovarian Cancer:Uterine Cancer

Stories to Watch

VIEW ALL

VIEW ALL

Advertisement

OncWeekly Featured Trials

Bladder CancerBreast CancerCervical CancerEsophageal CancerGastric CancerLung CancerLymphomaMelanomaOther CancersOvarian CancerPancreatic CancerProstate CancerSkin CancerAdavosertibAfatinibAfatinib DimaleateBinimetinibBiological: NivolumabBiological: PertuzumabBiological: RelatlimabBiological: TrastuzumabBiological: Trastuzumab EmtansineCapivasertibCopanlisibCopanlisib HydrochlorideCrizotinibDabrafenibDabrafenib MesylateDasatinibDefactinibDefactinib HydrochlorideErdafitinibFexagratinibIpatasertibLarotrectinibLarotrectinib SulfateOsimertinibOther: Cytology Specimen Collection ProcedureOther: laboratory biomarker analysisPalbociclibPI3K-beta Inhibitor GSK2636771Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Magnetic Resonance ImagingProcedure: Radiologic ExaminationSapanisertibSunitinib MalateTaselisibTrametinibUlixertinibVismodegibActiveNot RecruitingGuamPuerto RicoUnited States 8NCT02465060Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Cervical CancerBiological: bevacizumabBiological: PembrolizumabCarboplatincisplatinPaclitaxelPlacebo to pembrolizumabActiveNot RecruitingArgentinaAustraliaCanadaChileColombiaFranceGermanyIsraelItalyJapanKorea, Republic ofMexicoPeruRussian FederationSpainTaiwanTurkeyUkraineUnited States 9NCT03635567Phase 3
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Advertisement

Advertisement

LATEST

View More

Advertisement

Sign up for our Monthly emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy

Latest Conferences

VIEW MORE

3D View of Blood Cells on Breast Tumor
Breast Cancer

Enhanced Prognostication With Serial ctDNA Monitoring

KEY TAKEAWAYS The study aimed to assess the sensitivity of a personalized ctDNA assay (Signatera) in detecting molecular relapse in patients with BC during long-term follow-up. The study concluded that serial ctDNA tests aid prognosis, intervention, and monitoring...

May 2, 2024

Latest Conferences

VIEW ALL

VIEW ALL

RELATED CONTENT

VIEW ALL

Therapeutic Impact on OC Liver Metastases Survival

KEY TAKEAWAYS

  • The study aimed to investigate the trends in morbidity and mortality among patients with OC & liver metastases and assess the impact of various treatments on cancer-specific survival.
  • The primary endpoint was to determine OS & CSS.
  • Researchers noticed a declining trend in morbidity and mortality rates for patients with OC and liver metastases.

Na Li and the team aimed to examine the trends in morbidity and mortality among patients with ovarian cancer (OC) with liver metastases and investigate the impact of different treatments on both overall survival (OS) and cancer-specific survival (CSS). Notably, only surgery and chemotherapy conferred survival benefits to patients.

They performed an inclusive analysis involving 2,925 patients with OC with liver metastases from the Surveillance, Epidemiology, and End Results (SEER) database spanning 2010-2019. The primary endpoint focused on OS and CSS. Trend analysis was conducted to assess the incidence, OS, and CSS rates of liver metastases in OC.

Univariate and multivariate COX proportional risk models were utilized to explore the association between different treatment methods and OS, while univariate and multivariate competing risk models were employed to evaluate the impact of treatment methods on CSS.

At the end of follow-up, about 689 patients were alive. The OS and CSS rates were 76.44% and 72.99%, respectively. A significant decreasing trend was observed in the incidence (AAPC) = -2.3, 95% CI: -3.9, -0.7], all-cause mortality (AAPC = -12.8, 95% CI: -15.6, -9.9), and specific mortality (AAPC = -13.0, 95% CI: -16.1, -9.8) rate of liver metastases in OC.

After adjusting for all confounding factors, only receiving surgery was associated with improved OS (HR = 0.39, 95% CI: 0.31-0.48) and CSS (HR = 0.37, 95% CI: 0.30-0.47). Chemotherapy was also identified as a protective factor for OS (HR = 0.33, 95% CI: 0.30-0.37) and CSS (HR = 0.44, 95% CI: 0.39-0.50) in patients with OC.

Subgroup analyses revealed that surgery and chemotherapy remained significant protective factors for OS and CSS for patients without other distant metastases, with distant metastases to the bone, lung, brain, or other organs, with bone metastasis, and with lung metastasis.

The study concluded that a notable downward trend exists in morbidity and mortality rates among patients with liver metastases originating from OC. Only the receipt of surgery and chemotherapy as treatment modalities was associated with survival benefits for patients.

The study was sponsored by the Jilin Provincial Science and Technology Department Fund, Liaoning Provincial Science and Technology Talents, Natural Science Foundation, and Jilin Provincial Department of Education Fund.

Source: https://pubmed.ncbi.nlm.nih.gov/38635517/

Li N, Jin S, Wu J, et al. (2024). “Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER.” PLoS One. 2024 Apr 18;19(4):e0299504. doi: 10.1371/journal.pone.0299504. PMID: 38635517; PMCID: PMC11025763.

BEV Enhances Survival in Platinum-Resistant OC

KEY TAKEAWAYS

  • The study aimed to investigate the impact of BEV on survival outcomes in patients with PR-ROC in real-world clinical practice.
  • The primary endpoint was to determine PFS.
  • The study concluded that BEV improved OS in patients with PR-ROC, with manageable toxicity in real-world clinical practice.

Over the past several decades, advancements in anti-cancer drugs have significantly influenced the management of epithelial ovarian cancer (OC), improving patient outcomes. Among these drugs, BEV has emerged as a promising option for advanced or recurrent OC.

Aeran Seol and the team aimed to assess the effectiveness of BEV in patients with platinum-resistant relapsed epithelial ovarian cancer (PR-ROC).

They performed an inclusive analysis by retrospectively dividing patients with PR-ROC into two groups: BEV plus chemotherapy (BEV-CT group) and chemotherapy alone (CT group). The primary endpoint, progression-free survival (PFS), was compared between the two groups to assess whether survival outcomes were improved by adding bevacizumab.

Overall survival (OS) was compared to evaluate the impact of BEV on long-term survival outcomes in this patient population.

About 154 patients were included in the study. 57 in the BEV-CT group and 97 in the CT group. OS was significantly longer in the BEV-CT group compared to the CT group. The use of BEV was identified as a favorable prognostic factor for OS. Subgroup analysis focusing on 2L chemotherapy revealed statistically significant differences in PFS and OS between the two groups.

Additionally, a higher incidence of adverse hematologic events in grades 3 or above was observed in the CT group compared to the BEV-CT group.

The study concluded that in a real-world clinical setting, the introduction of BEV improved OS among patients with PR-ROC, with tolerable toxicity.

The study was sponsored by the National Research Foundation of Korea funded by the Ministry of Science and ICT, and the Cooperative Research Program of Basic Medical Science and Clinical Science of Seoul National University College of Medicine.

Source: https://pubmed.ncbi.nlm.nih.gov/38688599/

Seol A, Kim SI, Yoon HY, et al. (2024). “Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer.” In Vivo. 2024 May-Jun;38(3):1338-1350. doi: 10.21873/invivo.13574. PMID: 38688599.

Enhanced CAR T Targeting Mesothelin in OC: Clinical Insights

KEY TAKEAWAYS

  • The phase 1 trial aimed to investigate the enhanced in vivo anti-tumor activity of a fully humanized CAR T targeting mesothelin compared to a murine-derived counterpart, focusing on improving persistence and efficacy.
  • Researchers noticed enhanced M5 CAR T cell persistence in mesothelin-expressing cancers, suggesting avenues for improving clinical outcomes in CAR T cell therapy trials.

In the prior study, a CAR T using a murine-derived CAR construct targeted to mesothelin (SS1 CAR) demonstrated limited persistence and efficacy in ovarian cancer (OC).

Janos L. Tanyi and the team aimed to develop a fully human anti-mesothelin scFv fused to 4-1BB (CD137) and CD3zeta (M5 CAR). Pre-clinical evaluation revealed superior in vivo anti-tumor activity compared to SS1 CAR.

They performed an inclusive analysis to determine the maximum tolerated dose (MTD) of 3 x 107 CAR T-meso cells/m2. 19 patients with mesothelin-expressing tumors (14 ovarian, 1 lung, 4 malignant mesothelioma) were treated with the M5 CAR at this dose. 3 patients received a single IV dose of 3 x 107 CAR Ts without lymphodepletion (Cohort 1), 3 patients received a single IV dose of 3 x 107 CAR Ts following lymphodepletion (Cohort 2), and 2 patients received a single intrapleural CAR T infusion of 3 x 107 CAR Ts (cohort 3).

In repeated dose cohorts, 6 patients received an initial IV dose of 3 x 107 CAR T-meso cells/m^2 after lymphodepletion (Cohort 4), and another 5 patients received an intraperitoneal instillation of the same dose (Cohort 5), with all patients receiving up to two additional IV doses spaced 21-42 days apart.

About the treatment outcomes, M5 CAR T cells were detectable in the blood within 1 hour after infusion, peaking at Days 7-10, with higher levels observed in patients after lymphodepletion. Detectable M5 CAR T cells persisted in the blood for up to 28-42 days in all subjects, in 5 patients at 6 months, and in 4 patients at 18 months. M5 CAR T cells trafficked to the tumor in 13 out of 19 patients.

Using RECIST criteria, at 28-35 days after treatment, 13 patients showed stable disease (13/19, 68%) with a maximal target tumor volume decrease of 29.1%. A stable disease for 3 months in 4 patients was seen, and another had a stable disease for 21 months. Cytokine release syndrome (CRS) (1 Grade 3 and 3 Grade 4) was experienced by 9 subjects.

About 4 patients experienced Grade 4 serious adverse events (SAEs) (CRS, hypotension, hypoxia), and 14 patients had grade 3 SAEs (febrile neutropenia, abdominal pain, fatigue, CRS, hyponatremia, dyspnea, hypoxia, hypotension), with all subjects fully recovering.

The study concluded that M5 CAR T cells exhibited engraftment and expansion in the blood of all subjects, with prolonged persistence compared to SS1 CAR, and CAR T trafficking into tumors was identified in 13/19 patients. Despite short-term stable disease in most patients, no RECIST-defined clinical responses were observed. However, CAR T trafficking into tumors was identified in a significant portion of patients, indicating potential efficacy.

Furthermore, all routes of application were deemed safe and well tolerated. These findings suggest avenues for future clinical trials in CAR T cell therapy, particularly exploring combination approaches with oncoviruses, checkpoint inhibitors, or microenvironment modifiers to enhance trafficking, persistence, and clinical response.

The trial was sponsored by the University of Pennsylvania.

Source: https://sgo.planion.com/Web.User/AbstractDet?ACCOUNT=SGO&ABSID=461177&CONF=AM2024&CKEY=

Clinical Trial: https://clinicaltrials.gov/study/NCT03054298

Tanyi J.L., Haas A.R., Aggarwal C, et al. (2024). “Phase I clinical trial of autologous T cells bearing fully humanized chimeric antigen receptors targeting mesothelin with both intravenous administration and local delivery with or without lymphodepletion in mesothelin-expressing cancers, including ovarian cancer.” Presented at SGO 2024 (Abstract 2136).

Efficacy of R-DXd Monotherapy in OVC: Phase I Analysis

Efficacy of R-DXd Monotherapy in OVC: Phase I Analysis

KEY TAKEAWAYS

  • The phase 1 trial aimed to investigate the safety and efficacy of R-DXd in patients with previously treated OVC.
  • Researchers noticed promising safety and efficacy of R-DXd in patients with heavily pretreated OVC; further investigation is ongoing.

Raludotatug deruxtecan (R-DXd) is an antibody-drug conjugate comprised of a humanized IgG1 antibody against cadherin 6 (CDH6), a stable linker selectively cleaved within tumor cells and a membrane permeable topoisomerase I inhibitor. Expression of CDH6, a cell adhesion protein, is increased in the majority of epithelial ovarian cancer (OVC) cases and is associated with poor prognosis.

In this ongoing phase 1 trial, Kathleen N. Moore and the team aimed to evaluate the efficacy and safety of R-DXd, as a first-in-human trial in previously treated patients with OVC.

Researchers performed an inclusive analysis of patients with advanced epithelial OVC who had previously undergone taxane and platinum therapies. No patient pre-selection for any biomarker was employed. Part A of the study, which involved dose escalation, assessed the tolerability of R-DXd at 1.6 to 9.6 mg/kg. Subsequently, doses of 4.8 to 8.0 mg/kg were expanded in Part B; however, the 8.0 mg/kg cohort was closed due to the emerging risk-to-benefit ratio. A subgroup analysis of patients who received R-DXd at 4.8 to 6.4 mg/kg.

About 45 patients had received R-DXd at doses ranging from 4.8 (n=13), 5.6 (n=8), and 6.4 (n=24) as of 14 July 2023. Of the majority of patients across the 3 dose groups, 40 patients (88.9%) had platinum-resistant disease, and 29 (64.4%) with a significant portion having prior exposure to bevacizumab and PARP inhibitors. The median number of prior lines of therapy was 4 (range: 1–12). At the data cut-off, 30 patients (66.7%) were still on study treatment, with a median treatment duration of 17.9 weeks (range: 3.0–114.9).

Treatment-emergent adverse events (TEAEs) were experienced by 42/45 patients (93.3%), and grade ≥3 TEAEs were reported in 44.4% of patients. The most common any-grade TEAEs were nausea (57.8%), vomiting (40.0%), fatigue (37.8%), and diarrhea (31.1%). AEs led to R-DXd discontinuation in 5 patients (11.1%). The confirmed overall response rate (ORR), as per RECIST v1.1 criteria, was 48.6% (18/37; 95% CI: 31.9–65.6), with 1 patient achieving a complete response (CR) in a patient who received R-DXd at 4.8 mg/kg. Another 18 patients (48.6%) had achieved stable disease (SD).

The disease control rate was 97.4% (95% CI: 86.2–99.9), and the clinical benefit rate (CR+PR+SD lasting ≥180 days) was 50.0% (95% CI: 33.4–66.6). The median duration of response was 11.2 months (95% CI: 3.1–not estimable [NE]), and the median progression-free survival was 8.1 months (95% CI: 5.3–NE). In addition, preliminary correlation analyses between CDH6 expression and efficacy parameters will be presented.

The study concluded that R-DXd exhibited a manageable safety profile and promising preliminary efficacy in patients with unselected, heavily pretreated OVC. These findings provide valuable support for advancing further clinical development in OVC, as evidenced by the ongoing phase 2/3 trial (NCT06161025 [REJOICE-Ovarian01]).

The trial was sponsored by the Daiichi Sankyo.

Source: https://sgo.planion.com/Web.User/AbstractDet?ACCOUNT=SGO&ABSID=579345&CONF=AM2024&CKEY=

Clinical Trial: https://clinicaltrials.gov/study/NCT04707248

Moore K.N., Philipovskiy A, Harano K, et al. (2024). “Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase I study.” Presented at SGO 2024. (4)

Advancing MSS EC Therapy With MIRV + Pembrolizumab

KEY TAKEAWAYS

  • The phase 2 trial aimed to investigate the efficacy of MIRV in combination with pembrolizumab in improving the response to ICI in patients with MSS or pMMR EC.
  • The primary endpoints were to determine ORR and PFS.
  • Researchers noticed that the combination of MIRV and pembrolizumab shows promise in FRα-positive recurrent MSS/pMMR serous EC patients; further investigation is ongoing.

Folate receptor-alpha (FRα) expression correlates with poor prognosis in endometrial cancer (EC). Mirvetuximab soravtansine (MIRV), an antibody-drug conjugate (ADC) targeting FRα, demonstrated efficacy in Phase 1 trials in FRα-positive advanced/recurrent EC. MIRV’s mechanisms include target-mediated cytotoxicity and activation of monocytes, enhancing phagocytosis of tumor cells through Fc-FcγR interactions.

R. L. Porter and her team conducted a study by hypothesizing the MIRV’s potential to augment immune checkpoint inhibitors (ICI) response in microsatellite stable (MSS)/proficient mismatch repair (pMMR) EC, prompting a phase 2 investigation of MIRV plus pembrolizumab in recurrent/persistent EC.

They performed an inclusive analysis on patients with advanced or recurrent MSS/pMMR, FRα-positive (defined as ≥50% of tumor cells with ≥2+ staining on IHC by Ventana, Inc.) serous EC. Patients received MIRV 6 mg/kg AIBW and pembrolizumab 200 mg every 21 days until disease progression or unacceptable toxicity, with 1-3 prior lines of therapy allowed, including prior ICI therapy.

The co-primary endpoints were objective response rate (ORR) by RECIST 1.1 and the frequency of patients surviving progression-free for 6 months (PFS6). Sixteen patients were enrolled in Stage 1, with an additional 19 patients enrolled in Stage 2 if ≥2 objective responses or ≥2 PFS6 responses were observed. The combination would proceed further if 4 objective responses or 8 PFS6 events were achieved.

About 130 patient tumors were prescreened for FRα expression, revealing a median FRα of 30% (IQR: 5-55), with 43 (33.1%) classified as FRα positive (PS 2+ ≥50%). As of November 2023, 16 patients received study treatment, with a median follow-up of 4.7 months (IQR 2.9, 17.3). Among them, 6 patients (37.5%, 95% CI: 15.2-64.6%) achieved an objective response, including 1 confirmed complete response (CR) and 5 partial responses (PR) [3 confirmed (18.8%) and 2 unconfirmed (12.5%)]. Additionally, 31.3% (5/16) had stable disease, and 2 patients remained alive and PFS6.

The most common treatment-related adverse events (TRAEs) included AST elevation (50%), blurred vision (44%), fatigue (44%), and diarrhea (43%), with grade 3 TRAEs occurring in 2 patients (12.5%). Ocular toxicities of any grade were reported in 56.3% of patients. Updated efficacy and safety data and ongoing correlative studies will be presented at the meeting.

The study concluded that the combination of MIRV and pembrolizumab met the co-primary endpoint, indicating its potential for further investigation in FRα-positive recurrent MSS/pMMR serous EC. Ongoing investigations are focusing on identifying subpopulations most likely to benefit clinically from this combination therapy.

The trial was sponsored by the Dana-Farber Cancer Institute.

Source: https://www.abstractsonline.com/pp8/#!/20272/presentation/11425

Clinical Trial: https://clinicaltrials.gov/study/NCT03835819

Porter R. L., Xiong N., Tayob N., et al. (2024). “A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer.” Presented at AACR 2024 (Abstract CT008).

AP3S1: Vital in HGSOC Tumor Immunity and Prognosis

KEY TAKEAWAYS

  • The study aimed to investigate the role of AP3S1 gene mutations in driving tumorigenesis and potential therapeutic implications in HGSOC through WES analysis.
  • Researchers noticed that AP3S1 emerges as a promising therapeutic target in HGSOC, enhancing personalized treatment strategies and outcomes.

High-grade serous ovarian carcinoma (HGSOC) is a prominent subtype of ovarian cancer (OC), accounting for a substantial portion of OC-related mortality worldwide. Despite advancements in treatment, HGSOC patients face low overall survival (OS) rates, necessitating a deeper comprehension of the molecular underpinnings of tumorigenesis and identifying potential therapeutic targets.

Whole-exome sequencing (WES) is a potent tool for uncovering somatic mutations and alterations across the exome, offering crucial insights into the genetic drivers and molecular pathways involved in cancer progression.

Deshui Kong and the team aimed to assess the role of AP3S1, a gene identified through WES, in HGSOC pathogenesis and prognosis.

Researchers performed an inclusive analysis of WES results from tumor samples of 90 OC patients. The mutational landscape of these patients was compared with that of TCGA patients to identify similarities and differences. The sequencing data underwent bioinformatics analysis to explore tumor driver genes and their functional roles. Additionally, basic medical experiments were conducted to validate the results obtained from the bioinformatics analysis.

The WES unveiled the mutational profile of HGSOC, showcasing mutations in key genes such as BRCA1, BRCA2, and TP53. Notably, AP3S1 emerged as the most weighted tumor driver gene. Subsequent analysis of AP3S1 mutations and expression revealed associations with patient survival and the tumor immune response. Moreover, AP3S1 knockdown experiments in OC cells elucidated its regulatory role in tumor cell migration and invasion, primarily mediated through the TGF-β/SMAD pathway.

The study concluded that this comprehensive analysis of somatic mutations in HGSOC offers valuable insights into potential therapeutic targets and molecular pathways for targeted interventions. AP3S1 emerged as a key player in tumor immunity and prognosis, presenting new perspectives for personalized treatment strategies.

These findings significantly contribute to understanding HGSOC pathogenesis and lay a foundation for improved outcomes in patients with this aggressive disease.

This study was sponsored by Capital Health Research and Development of Special Fund, National Natural Science Foundation of China.

Source: https://pubmed.ncbi.nlm.nih.gov/38609993/

Kong D, Wu Y, Liu Q, et al. (2024). “Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.” Eur J Med Res. 2024 Apr 12;29(1):231. doi: 10.1186/s40001-024-01814-7. PMID: 38609993; PMCID: PMC11015698.

PARG Inhibition: A New DDR-Targeted Approach for OC

KEY TAKEAWAYS

  • The study aimed to investigate the efficacy of PARG inhibitors as alternative therapeutic strategies for overcoming resistance and immunosuppression in DDR-deficient OC.
  • Researchers noticed that targeting PARG in OC has dual benefits. This offers promise for overcoming resistance and improving immunotherapy efficacy.

Ovarian cancer (OC) poses a significant challenge due to its high mortality rates and limited treatment options post-standard therapy failure. Despite the effectiveness of poly(ADP-ribose) polymerase (PARP) inhibitors in DDR-deficient OC, resistance and immunosuppression hinder their efficacy, prompting the exploration of alternative therapeutic avenues. Poly(ADP-ribose) glycohydrolase (PARG) inhibitors present a promising class under investigation in preclinical and clinical cancer studies.

Antons Martincuks and the team aimed to assess the efficacy and potential of PARG inhibitors in overcoming resistance and immunosuppression in patients with OC.

Researchers performed an inclusive analysis using a PARG small-molecule inhibitor, COH34, and a cell-penetrating antibody targeting PARG’s catalytic domain to investigate its effects on signal transducer and activator of transcription 3 (STAT3) in OVCAR8, PEO1, and Brca1-null ID8 OC cell lines and immune cells.

The study examined PARG inhibition-induced effects on STAT3 phosphorylation, nuclear localization, target gene expression, and antitumor immune responses in vitro, patient-derived tumor organoids, and an immunocompetent Brca1-null ID8 ovarian mouse tumor model mirroring DDR-deficient human high-grade serous OC. The effects of overexpressing a constitutively activated STAT3 mutant on COH34-induced tumor cell growth inhibition were also tested.

The study observed that PARG inhibition effectively downregulates STAT3 activity via dephosphorylation in OC cells. Notably, the overexpression of a constitutively activated STAT3 mutant in tumor cells mitigates the growth inhibition induced by PARG inhibitors.

Moreover, PARG inhibition reduces STAT3 phosphorylation in immune cells, activating antitumor immune responses. These findings were evident in immune cells cocultured with OC patient tumor-derived organoids and in immune-competent mice bearing mouse ovarian tumors.

The study concluded that targeting PARG unveils a novel antitumor mechanism extending beyond its primary effects by inhibiting DDR in OC. Additionally, PARG inhibition triggers antitumor immune responses, suggesting a potential enhancement of response rates to immunotherapy among OC patients.

The study was sponsored by the City of Hope Markel-Friedman Accelerator Fund, and Grants from Rivkin Center for Ovarian Cancer and the Mary Kay Foundation (HY).

Source: https://pubmed.ncbi.nlm.nih.gov/38580335/

Martincuks A, Zhang C, Austria T, et al. (2024). “Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer.” J Immunother Cancer. 2024 Apr 5;12(4):e007716. doi: 10.1136/jitc-2023-007716. PMID: 38580335; PMCID: PMC11002370.

VIEW ALL

SELECT ONCOLOGY JOURNAL ARTICLES

Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T

Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T

Background Chimeric antigen receptor (CAR)-T cell quality and stemness are associated with responsiveness, durability, and memory formation, which benefit clinical responses. Autologous T cell starting material across patients with cancer is variable and CAR-T expansion or …

BMJ Journals